We use a few cookies

Essential cookies keep the library working. With your permission, we'd also like to use analytics to see what's useful and improve the experience. Read our Privacy Policy or Cookie Policy.

Skip to main content
Home/e-Resources/Medical Sciences/Aneurysm Study of Pipeline in an Observational Registry (ASPIRe)

Checking your access to this record.

Abstract & Overview

BACKGROUND AND OBJECTIVE: Few prospective studies exist evaluating the safety and efficacy of the Pipeline Embolization Device (PED) in the treatment of intracranial aneurysms. The Aneurysm Study of Pipeline In an observational Registry (ASPIRe) study prospectively analyzed rates of complete aneurysm occlusion and neurologic adverse events following PED treatment of intracranial aneurysms. MATERIALS AND METHODS: We performed a multicenter study prospectively evaluating patients with unruptured intracranial aneurysms treated with PED. Primary outcomes included (1) spontaneous rupture of the Pipeline-treated aneurysm; (2) spontaneous nonaneurysmal intracranial hemorrhage (ICH); (3) acute ischemic stroke; (4) parent artery stenosis, and (5) permanent cranial neuropathy. Secondary endpoints were (1) treatment success and (2) morbidity and mortality at the 6-month follow-up. Vascular imaging was evaluated at an independent core laboratory. RESULTS: One hundred and ninety-one patients with 207 treated aneurysms were included in this registry. The mean aneurysm size was 14.5 ± 6.9 mm, and the median imaging follow-up was 7.8 months. Twenty-four aneurysms (11.6%) were small, 162 (78.3%) were large and 21 (10.1%) were giant. The median clinical follow-up time was 6.2 months. The neurological morbidity rate was 6.8% (13/191), and the neurological mortality rate was 1.6% (3/191). The combined neurological morbidity/mortality rate was 6.8% (13/191). The most common adverse events were ischemic stroke (4.7%, 9/191) and spontaneous ICH (3.7%, 7/191). The complete occlusion rate at the last follow-up was 74.8% (77/103). CONCLUSIONS: Our prospective postmarket study confirms that PED treatment of aneurysms in a heterogeneous patient population is safe with low rates of neurological morbidity and mortality. Patients with angiographic follow-up had complete occlusion rates of 75% at 8 months.

Cite this record

David F. Kallmes, Waleed Brinjikji, Edoardo Pietro Boccardi, Elisa F M Ciceri, Orlando Diaz-Daza, Rabih G. Tawk, et al. (2016). Aneurysm Study of Pipeline in an Observational Registry (ASPIRe). Interventional Neurology, 5(1-2), 89–99. https://doi.org/10.1159/000446503

Copy in another style

Kallmes, D. F., Brinjikji, W., Boccardi, E. P., Ciceri, E. F. M., Diaz-Daza, O., Tawk, R. G., Woo, H. H., Jabbour, P. M., Albuquerque, F. C., & Chapot, R. (2016). Aneurysm Study of Pipeline in an Observational Registry (ASPIRe). Interventional Neurology, 5(1-2), 89–99. https://doi.org/10.1159/000446503
Author names are used as deposited, so check their order before you submit.

Metadata is harvested from open-access indexes and can be incomplete. Check a citation against the published version before relying on it — see our open access & attribution policy.